Basal cell carcinoma grows slowly enough that some people live with one for years before seeking treatment, but there is no safe window during which leaving it alone is harmless. Case reports document tumors neglected for a decade or more that eventually destroyed bone, invaded nerves, or grew to enormous sizes. The real danger is not that BCC will race through your body the way other cancers might, but that it will quietly eat into the tissue around it, turning what could have been a minor office procedure into a disfiguring surgical reconstruction or worse.
What Happens When a BCC Keeps Growing
BCC earned the old clinical nickname “rodent ulcer” because of what it does when ignored: it gnaws. The tumor is locally invasive, meaning it tends to burrow into nearby skin, cartilage, muscle, and bone rather than spreading to distant organs. A published case described a BCC of the ear that, left untreated, destroyed the entire outer ear and the underlying mastoid bone, involved the facial nerve, and eventually breached the dura surrounding the brain.1PubMed Central. Erosive rodent ulcer of the ear secondary to neglect Another report described a 61-year-old woman, herself a nurse, who noticed a lesion under her breast and waited roughly 15 years before seeking help. By the time she presented, the tumor measured 15 by 7 centimeters, had a central ulceration, and was invading underlying structures.2PubMed Central. A Rare Case of Neglected Giant Basal Cell Carcinoma in-Case Report and Literature Review
A review of the literature on mutilating facial BCCs concluded that the two most important factors in how destructive a tumor becomes are its anatomical site and the delay in seeking treatment.3British Journal of Oral and Maxillofacial Surgery. Mutilating basal cell carcinoma of the face In other words, the longer you wait and the closer the tumor sits to critical structures like the eye, ear, or nose, the worse the outcome. None of these giant or deeply invasive tumors appeared overnight. They are the end result of years of unchecked growth that could have been stopped when the lesion was still small.
The Metastasis Question
One reason people feel comfortable ignoring a BCC is the widespread belief that it “never spreads.” That belief is almost true, but not quite. Metastasis rates reported in the literature range from roughly 0.003% to 0.55%, depending on the study and patient population.4PubMed Central. Metastatic Basal Cell Carcinoma: A Rare Manifestation of a Common Disease One surgical series pegged the incidence of metastasis at about 0.1% among all BCC patients who underwent surgery.5PubMed. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature Those are reassuringly small numbers, but given that BCC is the single most common malignancy in fair-skinned populations, even a tiny percentage translates to real cases every year.
When BCC does metastasize, the spread tends to start through the lymphatic system before eventually reaching the bloodstream, with an early preference for regional lymph nodes.6PubMed Central. Metastatic basal cell carcinoma with atypical pattern of spread Lungs and bones are also common destinations.5PubMed. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature The tumors most likely to metastasize tend to be large, deeply invasive, or recurrent, which is to say, the ones that have been growing the longest or that were treated incompletely.
Not All BCCs Are Created Equal
The timeline question depends heavily on what type of BCC you have. Nodular BCC, the most common form, typically appears as a pearly or translucent bump and grows at a plodding pace. Superficial BCC is even more indolent and tends to spread outward across the skin surface rather than burrowing deep. These are the tumors that can sit quietly for years without causing dramatic destruction, though “not dramatic” and “not harmful” are different things.
The aggressive subtypes are a different story. Infiltrative and morpheaform (also called sclerosing) BCCs have a pattern of insidious growth with finger-like projections that extend well beyond the visible borders of the tumor. A study of bone-invading BCCs of the head found that the tumors were primarily nodular or nodular-infiltrating types, and every morpheaform variant in the study had invaded bone.7PubMed Central. Infiltrative Basal Cell Carcinoma of the Head: Factors Influencing Bone Invasion and Surgical Outcomes These subtypes can look deceptively flat or scar-like on the surface while tunneling deep underneath, which is part of why they get missed or underestimated.
Then there is basosquamous carcinoma, a hybrid that shares features of both basal cell and squamous cell carcinoma. It behaves more aggressively than typical BCC: its local recurrence rate after wide surgical excision can reach about 45%, roughly double that of standard BCC, and its metastatic potential falls in the range of 4 to 8%, which is far closer to squamous cell carcinoma than to ordinary BCC.8PubMed Central. Basosquamous Carcinoma: A Commentary A person waiting on a basosquamous carcinoma without knowing what subtype they have is taking a much larger gamble than someone with a nodular BCC.
Perineural Invasion and Hidden Spread
One of the less appreciated risks of letting a BCC grow is perineural invasion, where the tumor finds its way along the sheaths that surround nerves. This can happen silently at first, then eventually cause numbness, tingling, pain, or weakness in the affected area. One study found perineural invasion in about 20% of BCC cases examined, with higher rates in larger tumors, deeper tumors, and those classified as high-risk subtypes.9PubMed Central. Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion-Findings and Perspectives
A systematic review pooling data from 159 patients with BCC that had perineural invasion found a five-year cancer-specific mortality of about 8.5%, with more than a third of patients experiencing at least one recurrence. Male sex, involvement of multiple nerves, the presence of clinical symptoms such as pain or numbness, and perineural invasion visible on imaging were all tied to worse outcomes.10Dermatologic Surgery. Basal Cell Carcinoma With Perineural Invasion: A Systematic Review and Pooled Survival Analysis Those numbers stand in stark contrast to the near-zero mortality of straightforward, early-stage BCC, and they underscore why delay matters: tumors that have had time to infiltrate nerves are far harder to cure and far more likely to cause lasting damage.
Why People Wait
Understanding why BCC goes untreated for so long requires understanding human psychology as much as tumor biology. A study of patients with nonmelanoma skin cancer found that denial was the leading reason for delay, accounting for about 71% of cases. That category included people who thought the spot would go away on its own, assumed it was not important, were too busy, tried to self-treat, or were actually afraid to find out what it was. Scheduling difficulties explained another 10%.11PubMed. Delayed treatment and continued growth of nonmelanoma skin cancer Older patients were more likely to delay than younger ones, as were people with major life stressors and, perhaps counterintuitively, people who already had a history of cancer.
Separate research identified delayed diagnosis as more likely when patients were over 65, had never had a BCC before, lacked a family history of BCC, or had a lesion located somewhere other than the head or neck. Tumors that were not itchy or bleeding were also diagnosed later, presumably because they did not draw the patient’s attention.12PubMed. Factors related to delay in the diagnosis of basal cell carcinoma A case report from one institution highlighted how lack of access to primary care created a missed opportunity for earlier detection, allowing the BCC to grow destructively over time.13PubMed Central. Delayed Presentation of Basal Cell Carcinoma: A Case Report
When Misdiagnosis Extends the Wait
Sometimes the delay is not the patient’s choice at all. BCC can mimic other skin conditions, and if a clinician does not consider it, years can pass under the wrong diagnosis. One documented case involved a plaque that was managed as psoriasis for a full decade, treated with topical steroids and vitamin D creams. It was only after a new nodule appeared within the plaque that a biopsy was finally performed, revealing both a nodular BCC component and extensive superficial BCC underneath.14PubMed Central. Management of a large basal cell carcinoma masquerading as psoriasis using Mohs and serial excisions That is ten years of tumor growth during which the patient was actually seeking medical care and following a treatment plan. High-risk anatomical sites such as the eyelids and the skin around the eyes are areas where optometrists and other clinicians are in a position to catch BCCs before they reach an advanced stage.15Canadian Journal of Optometry. Basal Cell Carcinoma: A Series of Cases Optometry Should Not Miss
The Special Case of Frail and Elderly Patients
Not every untreated BCC represents neglect or missed opportunity. In older adults with significant health problems or limited life expectancy, deliberately choosing to watch a BCC rather than treat it can be a reasonable medical decision. An observational study of 280 BCCs in 89 patients managed with watchful waiting found that patient-related factors, including severe frailty, serious comorbidities, or limited life expectancy, were the reason for choosing observation in 83% of cases. The study concluded that watchful waiting may be appropriate for asymptomatic nodular or superficial BCCs in patients whose remaining lifespan is short.16PubMed Central. Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma An Observational Cohort Study of 280 Basal Cell Carcinomas in 89 Patients
A review in the dermatology literature framed the core question well: BCC is typically indolent, and mortality from it is rare, but untreated tumors can still erode quality of life through disfigurement, functional complications, secondary infections, pain, and psychological burden.17British Journal of Dermatology. Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting is appropriate? When watchful waiting is chosen, it should involve regular follow-up so that growth, bleeding, pain, or social withdrawal can trigger a shift back to active treatment.18PubMed Central. Complex Management of Basal Cell Carcinoma in a Frail Patient The decision is not “treat or ignore” but “treat now or monitor closely and treat if things change.”
Immunosuppressed Patients Face Higher Stakes
The slow, forgiving timeline that applies to most BCC patients does not apply to people with weakened immune systems, particularly organ transplant recipients on long-term immunosuppressive drugs. In that population, skin cancers tend to appear at a younger age, show up in multiple locations, and behave more aggressively than in immunocompetent patients.19PubMed Central. Coexistence of Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in a Renal Transplant Recipient: A Case Report These tumors carry a higher risk of both local and distant spread.20PubMed. High-risk cutaneous malignancies and immunosuppression: Challenges for the reconstructive surgeon in the renal transplant population For transplant recipients and others on immune-suppressing therapies, even a “low-risk” BCC warrants quicker action and closer surveillance than it would in someone with a normal immune system.
Can a BCC Disappear on Its Own?
There is a small but real phenomenon of spontaneous regression, where a BCC shrinks or vanishes without treatment. Case reports document instances in which a clinically apparent BCC resolved on its own, apparently driven by an immune response against the tumor.21PubMed Central. ‘The nodule that disappeared’ spontaneous regression of an eyelid noduloulcerative lesion mimicking the features of a basal cell carcinoma Researchers have found that regressing tumors show increased numbers of certain immune cells compared to tumors that keep growing, and that even the act of performing a biopsy may sometimes trigger an immune response that wipes out residual tumor. In one study, nearly half of BCCs initially sampled with a shave biopsy had no residual cancer left in the excision specimen, compared to none of the punch biopsy cases.22Journal of Clinical and Aesthetic Dermatology. Regression Rate of Basal Cell Carcinoma in a Veteran Population: A Study of 317 Cases at the Kansas City Veterans Affairs Medical Center
This is genuinely interesting biology, and it is the mechanism behind topical immune-stimulating treatments like imiquimod. But spontaneous regression is unpredictable and uncommon enough that no one should count on it. It is studied mainly for what it might teach us about harnessing the immune system against skin cancer, not as a reason to skip treatment.
What Happens When a Tumor Becomes Too Advanced for Surgery
Most BCCs are cured with straightforward surgical removal. But tumors that grow large enough, invade deeply enough, or recur enough times may reach a point where standard surgery is not feasible. For those patients, hedgehog pathway inhibitors like vismodegib became a significant advance. In a trial of patients with locally advanced BCC that could not be adequately treated with surgery or radiation, vismodegib produced an objective response rate of about 43%, including complete responses in roughly one in five patients.23PubMed Central. Efficacy and safety of vismodegib in advanced basal-cell carcinoma Among the patients enrolled, about 38% had tumors deemed inoperable outright, and the rest had disease where surgery would have meant severe deformity or had already failed.24PubMed Central. Targeted Therapy for Advanced Basal-Cellcinoma: Vismodegib and Beyond
For patients who progress on hedgehog inhibitors or cannot tolerate them, immunotherapy with the anti-PD-1 antibody cemiplimab offers a second-line option, producing responses in roughly 20 to 30% of patients with advanced BCC.25PubMed. Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma Response durations can be prolonged, making immunotherapy an important fallback.26PubMed Central. Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment These drugs exist because some BCCs do reach the point where a scalpel alone cannot solve the problem. They work, but not for everyone, and they come with side effects that a simple early excision would have avoided entirely.
The Financial Cost of Waiting
Beyond the physical toll, there is a concrete financial argument for early treatment. Tumor size is the main driver of treatment cost, surgical complexity, and the type of reconstruction required.27British Journal of Dermatology. Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening A real-world study of periocular BCC found that patients with extensive disease incurred substantially higher costs across the board: more outpatient visits, more surgeries, more radiation, and longer intervals between procedures. Total all-cause healthcare costs averaged about $37,000 for extensive disease compared to roughly $32,000 for limited disease, with surgery costs alone running about $3,700 versus $2,600.28PubMed. Healthcare Resource Utilization and Cost of Care in Patients With Periocular Basal Cell Carcinoma: A Real-World Study A small BCC removed in a single office visit with a simple closure is a fundamentally different expense and experience from one that requires staged excisions, flap reconstruction, and months of follow-up.
An Odd Wrinkle in the Mortality Data
Here is a finding that catches most people off guard: having a BCC may actually be associated with slightly lower overall mortality compared to the general population. A meta-analysis encompassing more than 464,000 BCC patients found a summary relative mortality of 0.92, meaning BCC patients were roughly 8% less likely to die of any cause during the study periods, though the result was not quite statistically significant. This contrasts sharply with squamous cell carcinoma, where patients showed about 25% higher all-cause mortality.29PubMed Central. All cause mortality in patients with basal and squamous cell carcinoma: A systematic review and meta-analysis
The likely explanation is not that BCC protects you but that people who get diagnosed with BCC tend to be the sort of people who see doctors regularly, have health insurance, and get skin checks. They are a self-selected healthier population in many respects. The tumor itself is rarely what kills anyone. But this statistic, reassuring as it sounds, only holds when people actually get treated. The case reports of neglected tumors invading the skull or destroying an eye socket are reminders that BCC’s low mortality rate is a consequence of treatment, not an inherent property of the disease.